Trial Profile
A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab for the Treatment Of Recurrent or Progressive Glioblastoma That Has Progressed on Bevacizumab
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jun 2019
Price :
$35
*
At a glance
- Drugs Carotuximab (Primary) ; Bevacizumab
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors TRACON Pharmaceuticals
- 07 Jun 2016 Primary endpoint has been met. (Determine median overall survival (OS) in patients with recurrent or progressive GBM who have progressed on bevacizumab.), as per an abstract presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 07 Jun 2016 Status changed from active, no longer recruiting to completed, as per an abstract presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology